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1. Introduction 
The need to treat the bone defects arises throughout the whole spectrum of orthopaedic 
surgery. It is possible to produce materials with specific mechanical properties, architecture 
and biodegradability. The essential attributes for regeneration of new osseous tissue include 
biocompatibility, osteointegration, osteoconductivity, osteoinductivity and osteogenicity. 
Biocompatibility means that the immunogenic response and foreign body reactions to the 
implanted material are minimised or absent. Osteointegration is defined as a process 
leading to close bonding of the newly formed mineralised tissue with the implant material. 
Beyond these bone regeneration essentials, other matrix properties can influence the 
suitability of a material for its intended clinical applications, such as surface roughness, the 
mechanical integrity of the matrix and the matrix’s porosity [1]. Several osteoconductive 
bone graft substitutes are available for clinical application, including coralline 
hydroxyapatite, collagen-based matrices, calcium phosphates, calcium sulphate and 
deproteinised bovine bone. These materials vary substantially in tems of their chemical 
composition, mechanical properties and biodegradability. Orthopaedic surgeons should 
understand the differences between the various bone graft substitutes to ensure they select a 
material that provides the desired properties for the intended clinical application. 
An ideal synthetic bone graft substitute should be a porous matrix with interconnecting 
porosity that promotes rapid bone ingrowth, and at the same time, it should possess a 
sufficient strength to prevent its crushing under physiological loads during osteointegration 
and healing. Hydroxyapatite (Ca10(PO4)6(OH)2), ǃ-tricalcium phosphate (Ca3(PO4)2), their 
derivatives and combinations are the most commonly used ceramic materials in orthopaedics. 
While hydroxyapatite ceramic materials provide an osteoconductive matrix for bone ingrowth 
and ongrowth, slow in-vivo resorption profiles can potentially limit their clinical applications 
[2]. Although ǃ-tricalcium phosphate ceramic has been studied substantially in animal models 
and its biocompatibility, osteoconductivity and resorbability have been reported, there have 
been only limited data regarding long-term outcome of its clinical use in surgery for bone 
tumours [3-12]. However, the informations about biological responses such as bone bonding 
and resorption of ceramics are very important in clinical applications [13-15].    
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The goal of this study was to analyze and compare the clinical and radiological outcome in 
patients after implantation of the nonresorbable oxyhydroxyapatite glass–ceramic and Beta-
Tricalcium phosphate used to fill the defects of long bones after curettage of bone cysts.  
2. Materials and methods 
2.1 Patients 
This retrospective study was approved by the local research ethics committee, and all 
participants gave their written, informed consent. We evaluated 39 consecutive patients  
who fulfilled the following inclusion criteria: (i) histologically confirmed unicameral bone 
cyst, (ii) treatment by curettage of the lesion and implantation of glass-ceramic or beta-
tricalcium phosphate, (iii) follow-up after at least 24 months to confirm a static radiographic 
outcome without recurrence of benign bone lesion. There were 28 male and 11 female 
patients. The age of the 21 patients with the implanted nonresorbable glass–ceramic at the 
time of surgery was 4–44 years with an average age of 15 years. The age of the 18 patients 
with implanted beta-tricalcium phosphate at the time of surgery was 7–30 years with an 
average age of 14 years. The unicameral bone cysts were located in the humerus (16 
patients), femur (13), fibula (4), tibia (2), calcaneus (2), ulna (1), and iliac bone (1). All 
patients had curettage of the cyst and filling of the resulting bone defect with glass–ceramic 
(15 male and 6 female) or tricalcium phosphate (13 male and 5 female). Cortical fenestration 
was carried out using an osteotome and the soft tissue membrane was removed by a curette. 
After the filling of the bone defect with glass–ceramic or tricalcium phosphate, the cortical 
window was replaced. Internal fixation was employed in four patients because a 
pathological fracture occurred in 3 cases and an impending fracture was in 1 patient. Splints 
or bandages were used postoperatively for patients judged to be at risk of pathological 
fracture. Full weight bearing was allowed after 8-12 weeks. The patients were scheduled for 
follow-up evaluations which included clinical and radiographic examinations at 4-6, 10-14 
weeks, 6 and 12 months intervals. Thereafter they were seen yearly.  
2.2 Filling 
A bioactive glass-ceramic material with wollastonite, oxyhydroxyapatite, residual glass 
phase, and whitlockite at a ratio of 45–30–20–5% (BAS-0, Lasak Ltd., Prague, Czech 
Republic) was used. The apatite-wollastonite glass-ceramic was dense with a porosity of less 
than 0.5%. The sintering temperature was 1200°C, the bending strength 170 MPa and the 
compression strength 400MPa. Granules 2–4mm in diameter were implanted during 
operations. The amount of the glass–ceramic used ranged from 5 to 45 g.  
β-tricalcium phosphate (Poresorb®, Lasak Ltd., Prague, Czech Republic) in granule form 
with particle size of 0,6 to 2 mm was implanted. The porosity of the interconnected ǃ-
tricalcium phosphate scaffold was 35±5 %, the average macropore size was 100 μm in 
diameter, the size of micropores was 1-5 μm, and the sintering temperature was 1180°C. The 
quantity of implanted β-tricalcium phosphate ranged from 3 to 66 g. 
2.3 Clinical and radiographic follow-up 
Clinical and radiographic examinations of all patients were carried out at 3–12 years (7 years 
on average) after implantation of the bioactive glass–ceramic and at 2–8 years (4 years on 
average) after implantation of tricalcium phosphate. The clinical follow-up included 
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subjective complaints, objective findings focused on soft tissue status in the area of synthetic 
bone graft substitute filling, range of movement in adjacent joints and weight-bearing ability 
of the treated extremity. The radiographs were taken in standard projections and evaluated 
independently by three investigators. The results were then compared for inter-observer 
agreement and, in case of differences, the patient´s radiograph was reviewed by all three 
observers together. The radiographic integration of bioactive glass–ceramic was evaluated 
according to the criteria of Uchida et al. [16] to determine the presence of the markedly seen 
bridging trabeculae at the recipient bone–implant interface and the amount of incorporation 
of glass–ceramic. The radiographic integration of tricalcium phosphate was classiffied 
according to the criteria of Nigro and Grace [17]. Complete integration was associated with 
radiographical homogeneity of host bone and bone graft substitute, and trabecular 
remodelling was seen. Integration was judged to be partial when the formation of a partial 
gap between synthetic bone graft substitute and host bone was observed. Resorption was 
defined as gradually decreased radiopacity of the bone graft substitute until complete 
resorption.  
3. Results 
3.1 AW glass-ceramic 
The clinical evaluation showed that 10 patients had no subjective complaints, 4 reported 
transient pain, 3 had pain at activity, 2 reported pain during weather changes, 1 woman 
observed pain during pregnancy, and 1 patient had pain at rest. No restriction in 
weightbearing of the limb treated was reported by any of the patients. Radiographs 
obtained immediately after surgery showed radiolucent zones between the implanted glass-
ceramic and the surrounding bone. Periodic assessments revealed that, during the period of 
3–4.5 months, the radiolucent zones faded and new bone developed. Continuing 
radiographic observations up to a maximum of 12 years after implantation have shown no 
evidence of biodegradation of the apatite-wollastonite glass-ceramic material. The distinct 
bridging bone trabeculae bound to the surface of glass-ceramic granules were observed in 
all patients (Fig. 1). In the metaphyseal region of long bones, the incorporated glass-ceramic 
granules still remained distinct and seemed to be connected to each other. However, in the 
diaphyseal region of long bones, there was little distinction between the glass-ceramic 
granules and adjacent bone. Increased bone density around the incorporated glass-ceramic 
material with remodeling of the cortex in the diaphyseal region of long bones was found in 
six of the nine patients. No degenerative changes were encountered in adjacent joints. No 
postoperative infections or fractures were observed in our patients. Recurrence of bone cysts 
was identified in one case. The patient had further curettage of recurrence located in the 
area surrounding an incorporated glass-ceramic material and the cavity was filled with 
allogeneic cancellous bone grafts; this patient had no pain. One male with a small residual 
defect required no further surgery. 
3.2 Tricalcium phosphate 
Neither postoperative infection nor adverse reaction due to the material were encountered. 
No patient complained of local pain af final examination and all patients were satisfied with 
their limb function. Radiographs obtained immediately after surgery demonstrated 
radiolucent zones between the implanted tricalcium phosphate and the surrounding bone. 
Over time, radiolucent zones faded and new bone developed in all 18 patients. The mean 
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e) 
Fig. 1. Anteroposterior radiograph of the left proximal femur showing a large unicameral 
bone cyst in a 13-year-old boy preoperatively  (a); complete filling of the curetted cavity 
with autologous cancellous bone grafts 2 months after surgery (b); recurrence of the cyst 4 
years later (c); complete filling of defect with apatite-wollastonite glass-ceramic granules 3 
months after curettage of the recurrence (d); bone trabeculae bound to the glass-ceramic 
granules which still remained distinct 10 years after surgery (e) 
period necessary for disappearance of these radiolucent zones was 9 weeks (range 5-13 
weeks). Periodic radiographic assessments revealed decreased radiographic density of β-
tricalcium phosphate and replacement of β-tricalcium phosphate granules by newly formed 
bone trabeculae. These processes apper to have started on the periphery of the synthetic 
filling and progressed centrally. Signs of the implanted β-tricalcium phosphate still 
remained radiographically at the final follow-up in all 18 cases, but the material was 
incorporated in the surrounding bone and gradually resorbed. 
Postoperative fractures were recorded in two patients with a unicameral bone cyst in the 
humerus. One male fell 3 weeks after surgery; the fracture was treated conservatively. The 
other male patient has had a car accident 20 months after surgery; the displaced diaphyseal 
fracture was treated with open reduction and plate osteosynthesis. In two young patients, 
growth arrest or deformity were seen before curretage of the cyst and implantation of β-
tricalcium phosphate. Premature closure of the physeal plate with resulting shortening of 
the upper extremity was found as a complications after pathological fracture of proximal 
humerus in one male with unicameral bone cyst. Recurrences of the unicameral bone cyst 
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were seen  only in 2 cases. Both patients had further curettage of recurrence in the area 
surrounding an incorporated tricalcium phosphate. In the skeletaly mature male patient, the 
cavity was filled with autologous cancellous bone grafts; in other patient, β-tricalcium 
phosphate was added to the cavity at the time of repeated curettage (Fig. 2). 
 
   
a)     b) 
   
c)     d) 
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e)     f) 
Fig. 2. Anteroposterior radiograph of the right proximal femur showing a large unicameral 
bone cyst in a 11-year-old boy preoperatively  (a); complete filling of the curetted cavity 
with β-tricalcium phosphate after surgery (b); decreased radiographic density of β-
tricalcium phosphate apparent on the periphery of filling with recurrence of the cyst 
localized between the implanted material and growth plate 7 months later (c); further 
progression of the recurrence 13 months after surgery (d); large multicameral recurrence of 
unicameral bone cyst in 15 years of age (e); β-tricalcium phosphate added to the cavity at the 
time of repeated curettage (f) 
4. Discussion 
Conventional bone grafting with an autologous bone harvested from the iliac crest is the 
current gold standard because the autografts contain marrow cells including 
nondifferentiated mesenchymal stem cells, osteogenic bone cells, an osteoconductive matrix 
and osteoinductive proteins. However, the availability of autologous bone grafts is limited, 
their harvesting requires a further operation with prolonged operative time and is often 
associated with donor-site morbidity. The processed allograft bone is an attractive 
alternative to the autologous bone [18]. These allogeneic bone grafts are primarily 
osteoconductive, but they retain a variable number of osteoinductive proteins. The host 
immune response to freezedried allografts is less vigorous than the response to fresh or 
fresh-frozen allografts [19]. The transmission of infectious agents from donor to recipient 
with allogeneic bone grafts is their major risk and a loss of mechanical properties is their 
important disadvantage. The infectious risk is increased when fresh allografts are used and, 
therefore, serological testing has to be performed to reduce that risk. 
In an effort to overcome limitations of autografts and allografts, the synthetic bone graft 
substitutes were developed from a variety of materials, including calcium phosphates, 
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calcium sulphates, bioactive glasses and glass-ceramics which appear to be the ideal 
substances for use as matrices because the inorganic component of bone is composed of 
hydroxyapatite. Bioceramics can be divided into three categories: bioinert ceramics 
(alumina), surface-bioactive ceramics (sintered hydroxyapatite, bioactive glasses and 
apatite-wollastonite glass-ceramics), and  resorbable bioactive ceramics (low-crystalline 
hydroxyapatite and tricalcium phosphate) [2].  
The used dense bioactive glass-ceramic with main crystalic phases, oxyhydroxyapatite, and 
wollastonite, when compared with beta-tricalcium phosphate ceramic, has no microporosity 
and nanoporosity. After the filling of the bone cavity with 2–4-mm granules of 
nonresorbable material, new bone tissue ingrowth was seen in the interspaces between 
granules [20,22]. The nonresorbable bone graft substitutes can offer an excellent permanent 
function in certain conditions. In contrast, these synthetic materials can also affect tissue 
reparation and function. After osteointegration of the rigid nonresorbable material, the 
surrounding bone tissue is often mechanically influenced and protected (the stress-shielding 
phenomenon), thereby changing the local mechanical signals. This adversely affects the 
surrounding bone tissue. The concentration of load stress at the interface of the rigid 
implant–bone tissue can generally cause pain or mechanical failure [21, 22]. Equalizing to 
the mechanical properties of the surrounding bone is essential, because the mechanical 
signals are important mediators for the differentiation of connective tissue progenitor cells.  
The ideal biodegradable bone graft substitutes should fulfill some requirements such as 
biocompatibility, adequate initial strength and stiffness, retention of mechanical properties 
throughout sufficient time to assure its biofunctionality and non-toxicity of the degradation 
by-products [23-25]. The continuous degradation of a resorbable material causes a gradual 
load transfer to the healing tissue, preventing stress-shielding phenomenon and stimulates 
the healing and remodeling of bones [22, 26]. The surgeon should be concerned with the 
mechanical and biological properties of the bone graft substitute as well as the handling and 
ability to assess healing of the grafted site. 
Aside from chemical composition, the microstructure (the volume, density and size of pores 
and interconnections, the specific surface) plays a role in the bone ingrowth of porous 
biomaterials. An increase of porosity would make bone ingrowth inside synthetic materials 
easier but would decrease their biomechanical properties. The interconnections in a porous 
material act only as pathways for nutritional elements, vascularization and cells between the 
pores that are the sites for bone tissue growth proceeding from the outside to the inside [2]. 
Therefore, the size of pores should be larger than the size of interconnections [27]. 
Macroporosity (pore size >50 μm), microporosity (pore size <10 μm) and pore wall roughness  
play an essential role in new bone formation [12, 28-33]. The larger surface area can support a 
higher bone inducing protein adsorption, ion exchange and bone-like apatite formation by 
dissolution and reprecipitation while the surface roughness enhances attachment, proliferation 
and differentiation of bone forming cells [2, 32]. Thus, these data imply that more extensive 
dissolution and reprecipitation of low-crystalline calcium phosphates can cause more 
osteoconductive and cell-mediated degradation characteristics [34]. 
Resorption is an important characteristic of bone graft substitutes and can be divided in two 
mechanisms: solution-mediated dissolution processes and cell-mediated (phagocytic) 
processes. The degradation attributes of calcium phosphates are dependent on the chemical 
composition, crystal structure, crystal and grain size, microporosity, neck geometry, and neck 
dissolution rates of the materials [34]. The density of pores and interconnections which 
expresses the quantity of connections between pores of porous materials plays a more 
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important role than their size that is modified during degradation of resorbable bioceramics, 
whereas the sizes and the densities are equally important in unresorbable biomaterials [2, 27]. 
Although tricalcium phosphate was incorporated in the surrounding bone and gradually 
resorbed, signs of the implanted β-tricalcium phosphate still remained radiographically in 
all cases. In our opinion, the implanted quantity of tricalcium phosphate was higher in our 
patients compared to other authors [5-7, 15]. More experimental and clinical studies will be 
required in order to resolve the healing problems of large bone defects combining scaffolds 
with osteoinductive factors and cell cultures. According to this study, interconnected ǃ-
tricalcium phosphate produced better clinical results than apatite-wollastonite glass-
ceramic. Interconnected ǃ-tricalcium phosphate is a successful and safe bone graft substitute 
for the treatment of benign bone tumours and tumour-like lesions because of its 
biocompatibility and bioresorbability.  
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